Get the Ricochet app

Ricochet will work fine in a browser on your mobile devices, but for the best experience please download our app.

Download on the App StoreGet it on Google Play

Become a member.

Tired of the toxicity of social media? Why not join Ricochet for just $5/month? Think of it as an online bar. Come in, have a drink, hang out, say whatever you want. But don’t badger, bully, or berate the other drinkers. That's our only rule.

HM

Hannah Mamuszka

Series

Hubwonk4 episodes

Recent Episodes

Hubwonk
Hubwonk

Breast Cancer Risk: Testing to Tailored Screening, Treatment, and Prevention

Joe Selvaggi talks with precision medicine expert, Alva 10 CEO Hannah Mamuszka about how individualized testing can both detect and substantially reduce the incidence of breast cancer, a disease that accounts for more than 40,000 deaths each year. Guests: Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Host:
Joe Selvaggi

April 2022

Hubwonk
Hubwonk

Pharmacy Benefit Profiteers: Distortions and Costs of Half-Trillion Dollar Drug Middlemen

Hubwonk Host Joe Selvaggi talks with ALVA10 Chief Executive Hannah Mamuszka and Dr. Blake Long about the perverse incentives imposed by Pharmacy Benefit Managers adding nearly $500 billion to U.S. drug costs. Guests: Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine. Dr. Blake Long is the Chief Medical Office of ALVA10. Blake was previously the Chief Medical Officer for Sapere Bio and for Echo Health Ventures, the venture investment group of BlueCross BlueShield of NC and Cambia Health Solutions. Prior to Echo, Blake served for 20 years as a practicing pediatric cardiologist at Savannah Children’s Heart Center and as a clinical professor at Mercer University School of Medicine. He earned his BA and MD from Duke University, and then completed his clinical training at Walter Reed Army Medical Center and Duke Medical Center. He received his MBA from Duke's Fuqua School of Business in 2015, and now is an Adjunct Professor at Fuqua in the Health Sector Management Program.
Host:
Joe Selvaggi

January 2022

Hubwonk
Hubwonk

Am I Contagious? Divining Covid’s Community Conundrum

Joe Selvaggi talks with Alva10 CEO and precision medicine expert Hannah Mamuszka about which tests are best for determining who is contagious and the implications for the CDC’s new isolation recommendations. Guest: Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Host:
Joe Selvaggi

June 2021

Hubwonk
Hubwonk

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute's Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary. Guest: Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine. Guest Host: Dr. William S. Smith is Pioneer’s Visiting Fellow in the Life Sciences.
Host:
Joe Selvaggi